SHINE Medical Technologies, Inc. (SHINE), a Wisconsin company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it has expanded its executive team with two important hires. Harsh Singh has joined the company as Chief Strategy Officer (CSO), and Nathan Schleifer has joined as General Counsel. CSO and General Counsel are two newly created roles that report directly to Greg Piefer, SHINE’s Chief Executive Officer and Todd Asmuth, SHINE’s President, respectively. In his role as Chief Strategy Officer, Mr. Singh will be responsible for fundraising, sales, marketing, investor relations, and corporate development. Mr. Schleifer will be responsible for overseeing the company’s global legal, intellectual property, and compliance efforts. The appointments come as the company begins construction of its main production facility on its Janesville, Wisconsin campus.
Mr. Singh comes to SHINE with 18 years of experience structuring private capital financings, public offerings such as IPOs, and strategic transactions. He has led strategy, business development, and general management positions at Fortune 500 companies in the nuclear medicine, medical device and pharmaceutical sectors. Mr. Singh also brings a background in investment banking, where he spent over 10 years covering the Life Sciences industry in New York and London. He received a BA in Economics and Mathematics from Wabash College and a Master of Business Administration in Finance and General Management from the University of Michigan – Stephen M. Ross School of Business.
Mr. Schleifer brings over 16 years of legal experience to his new role at SHINE. He began his career in the healthcare industry with API Healthcare, formerly a subsidiary of GE Healthcare. As their first attorney, Mr. Schleifer created the legal function and all associated processes. Most recently, Mr. Schleifer was Associated General Counsel to the leadership and management teams for YETI, where he created and implemented commercial, international, and intellectual property strategies, and helped the company go public in 2018. Mr. Schleifer received a BA in Mathematics and Philosophy from St. John’s College, a JD from Washington University, and a BS in Computer Engineering from Marquette University.
“Harsh’s demonstrated skill and experience in the pharmaceutical space, M&A, and financing are ideal for the Chief Strategy Officer role. He has a proven track record of strong leadership and achievement,” said Greg Piefer, CEO of SHINE. “Nathan’s thoughtful style and breadth of experience makes him an exceptional fit for the company. He is business-focused and understands how the legal function can support our company’s strategic objectives and positively impact growth. Both Harsh and Nathan are extraordinary additions to our executive team.”
“SHINE is making a powerful impact to the healthcare ecosystem by significantly improving the status quo for producing medical radioisotopes, an area of great unmet need that impacts millions of lives each year. I am grateful to be a part of such a wonderful purpose and an amazing team,” said Mr. Singh.
“I am excited to join a company with such a deep sense of purpose at a pivotal inflection point,” said Mr. Schleifer. “I look forward to playing a role in realizing Greg’s vision and playing a key role in SHINE’s long-term success.”
About Medical Isotopes
Medical isotopes are radioisotopes that are used in the diagnosis and treatment of disease. Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). The workhorse of nuclear medicine, Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce a variety of medical isotopes, including Mo‑99. Roughly 1% of all Mo-99 in the world decays every hour, meaning it must be continuously produced. Current production is limited to only a handful of government-owned nuclear research reactors, the majority of which are overseas.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. In 2017, SHINE built the first building on its Janesville campus: SHINE Building One. Learn more at http://shinemed.com
;
